Idzerda L, Rader T, Tugwell P, Boers M. Can we decide which outcomes should be measured in every clinical trial? A scoping review of the existing conceptual frameworks and processes to develop core outcome sets. J Rheumatol 2014;41:986–93; published online before print: doi:10.3899/jrheum.131308
The following paragraph was omitted from the original:
In the scoping review of processes used to develop core sets1, the summary of the work done in eczema (Table 3) was incomplete, listing only the initial systematic review. Briefly, the Harmonising Outcome Measures for Eczema (HOME) initiative2 is an international multiprofessional group that aims to standardize and validate a core set of outcome measurement instruments for atopic eczema. Following a systematic review3 on the domains and instruments to measure aspects of severity of eczema, a multiperspective consensus panel was established consisting of patient representatives, clinicians, journal editors, and regulators to define a core set of outcome domains for eczema trials and for record keeping in routine care4. Delphi methods and nominal group technique have been used in the development process5. HOME has been linked with Outcome Measures in Rheumatology Clinical Trials (OMERACT) from the beginning, and is applying the OMERACT filter6 as a criterion to recommend outcome measurement instruments7.
We regret the omission.
REFERENCES
- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.